Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320827
Status:
COMPLETED
Last Update Posted:
2007-09-11
First Post:
2006-04-28
Brief Title:
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas Without Leukemic Component
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Study Overview
Official Title:
Phase 1 Study of CS-1008 a Humanized Monoclonal Antibody Targeting Death Receptor 5 DR5 Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas Without Leukemic Component
Status:
COMPLETED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a dose escalation study of CS-1008 humanized anti-DR5 antibody to determine the recommended Phase 2 dose and the maximum tolerated dose Drug will be administered for six weeks and possibly up to 12 weeks depending on response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None